6CM
CODX

683 Capital Management’s Co-Diagnostics CODX Stock Holding History

683 Capital Management’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,233
Closed -$229K – 280
2022
Q1 		$229K Hold
1,233
– – 0.01% 259
2021
Q4 		$330K Buy
+1,233
New +$323K 0.01% 260

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

683 Capital Management's CODX Position: Q2 2022 in Review

683 Capital Management sold out of Co-Diagnostics (CODX) in Q2 2022, closing a stake of 1,233 shares — an estimated $229K sold.

683 Capital Management first reported a position in CODX in Q4 2021 and held it in 2 quarters. The position peaked at $330K in Q4 2021. 69 funds tracked by Wall St. Rank hold CODX as of Q2 2022.

  • 683 Capital Management reported no remaining Co-Diagnostics position as of Q2 2022 after selling out during the quarter.
  • 683 Capital Management sold 1,233 Co-Diagnostics shares in Q2 2022, an estimated $229K.
  • 683 Capital Management first reported a position in Co-Diagnostics in Q4 2021 and held it in 2 quarters.
  • 683 Capital Management's Co-Diagnostics position peaked at $330K in Q4 2021.
  • 69 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2022.

Based on 683 Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.